
01-05-07





## FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10

EV304413601US Express Mail Label Number January 4, 2007 Date of Deposit

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

**ART UNIT: 1645** 

ROSOK, ET AL.

EXAMINER: DEVI, SARVAMANGALA J N

**APPLICATION NO: 08/905,293** 

FILED: 08/01/1997

FOR: METHOD FOR INHIBITING IMMUNOGLOBULINS IN THERAPY

AND IN VIVO DIAGNOSIS

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

## SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

This Information Disclosure Statement is being filed in accordance with 37 C.F.R. §1.97(c).

In accordance with 37 C.F.R. §1.56, applicant wishes to call the Examiner's attention to the reference cited on the attached form(s) PTO-1449. The listed reference was cited in an Office Action in a corresponding European application.

A copy of this reference is enclosed herewith.

**ON0146A NP** 

## Statement Under 37 C.F.R. § 1.704(d) and 1.97(e)(1)

I, the undersigned attorney, hereby certify that each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application and that no individual designated in 37 C.F.R. §1.56 (c) received that communication more than 30 days prior to the filing of this Information Disclosure Statement.

The Examiner is requested to consider the foregoing information in relation to this application and to indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s). It is believed that no fees are due in connection with the filing of this Information Disclosure Statement. If that belief is incorrect, please charge any required fees to Deposit Account 19-3880 in the name of Bristol-Myers Squibb Company.

Respectfully submitted,

Bristol-Myers Squibb Company Patent Department P.O. Box 4000 Princeton, NJ 08543-4000

Todd Spalding
Attorney for Applicant

Reg. No. 55,638

Phone: 609-252-3034 Date: January 4, 2007

PTO/SB/08B (	

Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

ostitute for form 1449/PTO		COMPLETE IF KNOWN		
ibstitute for form 1449/PTO			Application Number	08/905,293
		Filing Date	08/01/1997	
STATEMENT BY APPLICANT(S) (use as many sheets as necessary)			First Named Inventor	MAE JOANNE ROSOK
			Art Unit	1645
			Examiner Name	DEVI, SARVAMANGALA J N
neet	of	1	Attorney Docket Number	US - NP

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article(when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	Check box if English language Translation is attached	
	AA	Canfield, et al., "The Binding Affinity of Human IgG for its High Affinity Fc		
		Receptor Is Determined by Multiple Amino Acids in the C <sub>H</sub> 2 Domain and Is		
*		Modulated by the Hinge Region", J. Exp. Med., Vol. 173, pp. 1483-1491 (1991)		
	4			
١				
	İ			

Examiner	Date
Signature	Considered

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant